Switching to raltegravir in virologically suppressed in HIV-1-infected patients: A retrospective, multicenter, descriptive study

Daniel Podzamczer*, Esteban Martínez, Pere Domingo, Elena Ferrer, Pompeyo Viciana, Jordi Curto, Maria Jesús Pérez-Elías, Antonio Ocampo, Ignacio Santos, Hernando Knobel, Vicente Estrada, Eugenia Negredo, Ferrán Segura, Joaquín Portilla, Esteban Ribera, Josefa Galindo, Antonio Antela, Jorge Carmena, Manuel Castaño

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

Objectives: To describe the efficacy and tolerability of switching to raltegravir (RAL) in virologically suppressed HIV-1-infected patients during routine clinical practice. Methods: A total number of 263 subjects (189 men, median age 48.1 years) with HIV-1 RNA < 50 copies/mL for ≥ 6 months were switched to RAL (400 mg b.i.d). Reasons for change were toxicity (49.0%), drug interactions (6.1%) or convenience (28.6%) (switch from subcutaneous to oral treatment 22.4%, improvement of posology 3.4%). Patients were followed up to 24 months after switching to RAL. Primary end-points were tolerability and virological failure defined as two consecutive measures of HIV-1 RNA > 50 copies/mL. Results: After a median of 12.4 months (range 2.8-26.4 months), virological failure was observed in 6 (2.3%) patients (2.2 per 100 person-years [95%CI 0.9-4.6]), while AIDS occurred in 1, drug discontinuation in 4, 3 patients died and 10 were lost to follow-up. The median CD4+ T cell count increased from 460 cells/mm3 to 508.6 cells/mm3 (P < 0.001). Conclusions: Switching to RAL in clinical practice was mainly driven by toxicity, convenience or interactions, they were well tolerated and secured virologic suppression in the vast majority of patients.

Original languageAmerican English
Pages (from-to)673-678
Number of pages6
JournalCurrent HIV Research
Volume10
Issue number8
DOIs
Publication statusPublished - 2012

Keywords

  • HIV infection
  • Raltegravir
  • Simplification strategy
  • Toxicity

Fingerprint Dive into the research topics of 'Switching to raltegravir in virologically suppressed in HIV-1-infected patients: A retrospective, multicenter, descriptive study'. Together they form a unique fingerprint.

Cite this